Efficacy of Oral Intake of Hydrogen-Rich Jelly Intake on Gingival Inflammation: A Double-Blind, Placebo-Controlled and Exploratory Randomized Clinical Trial.
Takayuki Maruyama, Eiji Takayama, Shinichi Tokuno, Manabu Morita, Daisuke Ekuni · Healthcare (Basel, Switzerland) · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
Administration of hydrogen-rich jelly for 14 days decreased gingival inflammation.
What the Researchers Studied
The study used a placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Were instructed to orally ingest 30 g of hydrogen-rich jelly (experimental group) or placebo jelly (control group) three times a day (after each meal) for 14 consecutive days. The hydrogen-rich jelly used in this study was manufactured by Shinryo Corporation (Kitakyushu, Fukuoka, Japan). Administration of hydrogen-rich jelly for 14 days decreased gingival inflammation. This study found that ingestion of hydrogen-rich jelly for 14 days tended to reduce serum oxidative stress and suppress increases in the oxidative index. These findings suggest that the effects of hydrogen-rich jelly on systemic oxidative stress are shown after more than 14 days.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The study used a placebo-controlled human clinical trial. The hydrogen delivery method was hydrogen-supplemented jelly intake.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.